Pharma Pulse: Medicare's GLP-1 Bridge and FDA's PreCheck Program

Pharmaceutical Commerce· July 1, 2026

Medicare is reportedly exploring a coverage bridge for GLP-1 medications, a move that could significantly expand patient access to these high-demand treatments for weight management and diabetes. Simultaneously, the FDA is advancing its PreCheck program, which aims to streamline regulatory oversight and improve efficiency for pharmaceutical manufacturers. These developments represent pivotal shifts in federal healthcare policy that could reshape market dynamics and operational standards across the pharmaceutical sector.

Read the full story at Pharmaceutical Commerce

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Pharmaceutical Commerce.

More in Pharmaceutical

Bristol-Myers Squibb Hires Lobbyist on Health Issues

Bristol-Myers Squibb has engaged Alexander J. Beckles LLC to represent the company on health policy matters following a new lobbying disclosure filed in late June 2026. This move comes as the pharmaceutical giant faces increased scrutiny from lawmakers regarding its drug pricing practices and recent price hikes on key medications. The engagement signals a strategic effort by the company to navigate a complex regulatory environment and influence ongoing congressional debates over medical pricing.

July 1, 2026

Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program

The FDA has officially launched its PreCheck pilot program, selecting seven pharmaceutical and biotechnology companies to receive specialized regulatory guidance for new domestic manufacturing facilities. This initiative, stemming from a 2025 executive order to promote U.S. drug production, aims to streamline the establishment of production sites through technical support and pre-submission meetings. By reducing regulatory barriers, the program seeks to accelerate the domestic supply of critical therapies ranging from blockbuster obesity treatments to advanced gene therapies.

July 1, 2026

Anthropic Launches Claude Science for Pharma Research as Trump Drug Pricing Plan Faces Hurdles

Anthropic has introduced Claude Science, a specialized AI interface designed to optimize large language models for pharmaceutical research and laboratory operations. Meanwhile, a Medicaid pilot program is testing the feasibility of President Trump’s "most-favored-nation" drug pricing plan among mid-sized and smaller pharmaceutical companies. These developments highlight the industry's dual focus on integrating advanced AI into drug discovery while navigating aggressive new federal pricing regulations.

July 1, 2026

US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

The U.S. Food and Drug Administration has expanded the approval of Vertex Pharmaceuticals' gene therapy for sickle cell disease to include pediatric patients as young as two years old. This regulatory milestone broadens the reach of a treatment for a debilitating genetic blood disorder that can cause severe pain and long-term health complications. For the pharmaceutical sector, this expansion represents a significant step in the commercialization and accessibility of gene therapies for younger populations. The decision highlights the agency's willingness to authorize advanced genetic treatments for pediatric use following initial adult approvals.

July 1, 2026